Double Filtration Plasmapheresis in the Treatment of Antineutrophil Cytoplasmic Autoantibody Associated Vasculitis With Severe Renal Failure: A Preliminary Study of 15 Patients
Authors:
- 7 March 2016
- journal article
- Published by Wiley in Therapeutic Apheresis and Dialysis
- Vol. 20 (2) , 183-188
Abstract
Our aim was to investigate the clinical efficacy of double filtration plasmapheresis (DFPP) in the treatment of antineutrophil cytoplasmic autoantibody‐(ANCA) associated vasculitis (AAV) with severe renal involvement. Fifteen AAV patients who had severe renal failure (median SCr 5.6(IQR 5.2–9.0) mg/dL) and needed initial renal replacement therapy (RRT) were treated with DFPP and immunosuppressive therapy. Two plasma volumes were processed during each DFPP session. The changes of serum ANCA and renal function were investigated. After the DFPP treatment for three to five sessions, serum MPO‐ANCA level decreased from 250.0 ± 86.9 RU/mL to 70.5 ± 64.7RU/mL (P = 0.00), with a median reduction rate of 67.6%. Eleven patients (73.3%) no longer needed from RRT 3 months after DFPP treatment, while another four patients remained on dialysis. During the follow up for median 10 (IQR 6–24) months, SCr level decreased to normal in one patient, one patient progressed into ESRD. The 1 year renal survival rate was 62.9%. Five (33.3%) patients were complicated with pulmonary infection. DFPP combined with immunosuppressive therapy could increase the renal recovery rate through rapidly decreasing serum ANCA levels for AAV patients with severe renal failure, but its clinical efficacy and impact on long‐term renal survival require further studies.Keywords
This publication has 18 references indexed in Scilit:
- Intravenous Cyclophosphamide and Plasmapheresis in Dialysis-Dependent ANCA-Associated VasculitisClinical Journal of the American Society of Nephrology, 2013
- More Selective Removal of Myeloperoxidase‐Anti‐Neutrophil Cytoplasmic Antibody From the Circulation of Patients With Vasculitides Using a Novel Double‐Filtration Plasmapheresis TherapyTherapeutic Apheresis and Dialysis, 2012
- Biomarkers of endothelial dysfunction in patients with primary focal segmental glomerulosclerosisNephrology, 2012
- Plasma exchange in the treatment of Wegener's granulomatosis, microscopic polyangiitis, Churg–Strauss syndrome and renal limited vasculitisCurrent Opinion in Rheumatology, 2011
- Histopathologic Classification of ANCA-Associated GlomerulonephritisJournal of the American Society of Nephrology, 2010
- Randomized Trial of Plasma Exchange or High-Dosage Methylprednisolone as Adjunctive Therapy for Severe Renal VasculitisJournal of the American Society of Nephrology, 2007
- Advances in apheresis therapy for glomerular diseasesClinical and Experimental Nephrology, 2007
- Cinical and pathological characteristics of Chinese patients with antineutrophil cytoplasmic autoantibody associated systemic vasculitides: a study of 426 patients from a single centrePostgraduate Medical Journal, 2005
- Diabetes Mellitus Associated with Rapidly Progressive Glomerulonephritis with Perinuclear Antineutrophil Cytoplasm Antibodies.Internal Medicine, 2000
- Nomenclature of Systemic VasculitidesArthritis & Rheumatism, 1994